Among the many, sexually transmitted infections are Mycoplasma Genitalium. This is a small pathogenic bacterium that lives on mucous epithelial cells of the genital and urinary tract. Medical reports show that this infection is increasing in number.
Symptoms
Symptoms of Mycoplasma Genitalium can vary from person to person. They may occur within a few days to a couple of months of the infection. They include pain, fever, cough, and fatigue. If you are experiencing any of these symptoms, you should consult your physician.
Mycoplasma genitalium (Mgen) is a sexually transmitted disease (STD) that affects both men and women. It is highly contagious among people who have many sexual partners and is most common in people who do not practice safe sex.
Mycoplasma genitalium can be diagnosed by examining a person’s urine. A nucleic acid amplification test, also called a Mycoplasma genitalium test, looks for the genes of bacteria that are present in the urine. The test is available at several private clinics and is usually performed at the same time as a standard STI test. The cost of the Mycoplasma genitalium test ranges from PS65 to PS80.
People can also be diagnosed by taking a swab from the vagina, penis, or throat. The swab is then sent to a laboratory for a Mycoplasma genitalium lab test. The lab tests look for bacteria that are resistant to certain antibiotics.
Mycoplasma genitalium is usually treated with antibiotics. However, a patient may be infected for many years without showing symptoms. This makes it difficult to diagnose.
If you think you have been infected with Mycoplasma genitalium, you should consult your physician. You should avoid sexual contact if you are experiencing symptoms. A doctor can also check for other sexually transmitted diseases.
You should also tell your doctor if you are pregnant. If a woman is infected with Mgen, the infection can spread from her to her baby. It can also cause ectopic pregnancy, which is a serious complication.
Aside from treatment, you can also help to prevent complications by using barrier protection during sexual contact. Also, you can use herbal supplements to boost your immune system. You can also use condoms to prevent the transmission of the disease.
The infection may also cause pelvic pain and infertility. In addition, it can cause a severe infection in the cervix and fallopian tubes. It can also cause urethritis, an inflammation of the urethra.
Diagnosis
Detection of Mycoplasma genitalium is an important step in assessing the risk of sexually transmitted infection. This type of infection is associated with pelvic inflammatory disease in women, nongonococcal urethritis in men, and an increased risk for HIV infection. However, it is still difficult to detect Mycoplasma genitalium with traditional laboratory methods.
One approach to diagnosing Mycoplasma genitalium is with the use of nucleic acid amplification testing. This approach searches for genes that bacteria use to reproduce. Research into developing such tests has been focused on the Mycoplasma genitalium species.
A study was conducted to compare a real-time quantitative PCR assay for Mycoplasma genitalium with a commercial assay. The study included 11,774 samples. The assays were designed to target the pdhD gene, which encodes dihydrolipoamide dehydrogenase. The amplification was carried out on 82-base pair fragments of M. genitalium DNA. The assay demonstrated a detection limit of 300 genome copies/mL.
However, research into commercial assays for Mycoplasma genitalium is still limited. While diagnostic tests are available in Europe, they are not yet approved in the United States. This is a major problem, as more tests are needed to drive the agenda forward.
The test, called the Aptima Mycoplasma genitalium Assay, is a nucleic acid amplification test that detects Mycoplasma genitalium in urine samples. The test is effective in 90 percent of samples. The test can be used for women and men and can be performed on vaginal swabs, urine samples, and discharge from the urethra. The assay can be used for testing patients in the clinic or for community-based screening programs.
The test is approved through the De Novo premarket pathway, which establishes special controls to ensure the accuracy and reliability of the test. In addition, the test is tested by external quality assessment programs, which require the laboratories to participate.
Detection of Mycoplasma is still challenging, particularly in the current era of antimicrobial resistance. Treatment for Mycoplasma is usually administered with antibiotics. The rate of azithromycin resistance has increased, which has increased the need for commercial diagnostic assays. It is essential to establish cost-effective and widespread diagnostic testing.
Treatment
Despite the prevalence of sexually transmitted diseases, Mycoplasma genitalium remains largely unrecognized. This is in part due to the difficulty of isolating the bacteria, as well as the lack of commercial molecular-based tests. However, Mgen can be detected with laboratory tests that are performed on swabs taken from a woman’s vagina.
Although there is no clear clinical guideline on how to treat Mgen, it is important to treat it sooner rather than later. This helps to reduce the risk of reinfection and the development of resistance.
Treatment of Mgen should be considered in cases of persistent cervicitis and in women who develop the pelvic inflammatory disease. Men who develop urethritis or menstrual dysfunction are also at risk of infection with Mgen.
The majority of Mycoplasma genitalium infections are treated in the context of syndromic management for urethritis, cervicitis, or PID. In cases of persistent PID, an alternative treatment strategy can include combination therapy of doxycycline and a macrolide. However, this is not recommended for pregnant women who are planning a child.
Azithromycin, the most widely prescribed treatment for Mgen, is administered in an extended dose regimen over five days. It is currently effective in most cases but is also associated with increasing resistance. Therefore, a more conservative regimen is recommended for patients who experience resistance. Azithromycin alone is ineffective in 50 percent of patients.
Azithromycin is also used as a second-line treatment for cases that do not respond to doxycycline. The tolerability of the regimen is poorer than monotherapy, but it can be beneficial in preventing the development of resistance.
Another option for treating Mgen is to try a combination of nonquinolone antimicrobials. These antimicrobials inhibit protein synthesis, which is a main physiologic target for Mgen. In addition, a combination of these drugs has shown positive results in vitro.
However, the effectiveness of combination therapy in preventing the development of resistance is not known. However, a single-dose azithromycin regimen has been shown to have cure rates of 60 to 85 percent. In addition, patients with complicated infections are treated with an extended course of moxifloxacin.
Prevention
During the past two decades, Mycoplasma genitalium has become a major STI pathogen. The infection is associated with pelvic inflammatory disease and infertility. It can be treated with antibiotics but is becoming increasingly resistant. This makes the treatment regimens difficult to implement.
As a sexually transmitted infection, Mycoplasma genitalium can be prevented through condom use. Women should also inform their sexual partners about the infection, thereby lowering the risk of reinfection. However, there is no national treatment guideline.
The Centers for Disease Control and Prevention (CDC) has published guidelines for the treatment of sexually transmitted diseases (STIs). These guidelines recommend a sexually transmitted disease vaccination program, including hepatitis A and a hepatitis B vaccine.
Mycoplasma genitalium is an emerging STI, but there is limited data to support widespread screening. The lack of a national program for the infection makes it unlikely that it will be reportable in any area of the United States.
There is a need for better information about the natural history of infection, which will be needed to evaluate the value of potential screening programs. A rigorous evaluation of a screening program may be useful in refining clinical management algorithms.
Screening programs should be informed by randomized controlled trials, evaluating the impact on major reproductive health morbidities in women. There should also be cost-effectiveness analyses. Moreover, additional prospective randomized studies are needed to evaluate therapeutic strategies.
Sentinel surveillance at specialized STD clinics could be a useful tool in defining the prevalence of infection. In addition, population-level trials could evaluate the impact of serial rounds of screening on M. genitalium incidence and prevalence.
Mycoplasma genitalium testing should not be conducted for symptom-based testing but should be limited to women at risk of an STI. There should also be efforts to prevent antimicrobial resistance. This means that women who are infected should not be prescribed antibiotics that can be resistant to the infection.
Mycoplasma genitalium infection is often asymptomatic. However, it can cause pelvic inflammatory disease, infection of the cervix, and tubal infertility. The infection can also be a cause of abnormal vaginal bleeding between periods.
Health Sources:
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/
